CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

April 30, 2026

Study Completion Date

February 29, 2040

Conditions
Hodgkin's LymphomaNon-Hodgkin Lymphoma
Interventions
GENETIC

CAR T Cells

"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2."

Trial Locations (2)

77030

RECRUITING

Houston Methodist Hospital, Houston

RECRUITING

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

lead

Baylor College of Medicine

OTHER

NCT02917083 - CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) | Biotech Hunter | Biotech Hunter